Insiders · Profile

Cordova Ashley

Chief Executive Officer at NovoCure. Filing since 2 Nov 2020. CIK 0001822014

Company
Date
Role
Action
Shares
Amount
Of holding
5 Sep 2025
Chief Executive Officer
Bought
81,550
$996.86K
22.9%
3 Mar 2025
Chief Executive Officer
Sold at will
2,053
$38.06K
1.0%
28 Feb 2025
Chief Executive Officer
Sold at will
2,341
$42.80K
1.1%
27 Feb 2025
Chief Executive Officer
Sold at will
11,153
$223.32K
5.1%
2 Aug 2024
Chief Financial Officer
Sold at will
688
$13.86K
0.3%
1 Sep 2023
Chief Financial Officer
Sold at will
883
$19.26K
0.9%
2 Aug 2023
Chief Financial Officer
Sold at will
1,144
$34.61K
1.1%
3 Mar 2023
Chief Financial Officer
Sold, plan not stated
5,505
$419.26K
5.2%
2 Mar 2023
Chief Financial Officer
Sold, plan not stated
1,055
$79.42K
1.1%
1 Mar 2023
Chief Financial Officer
Sold, plan not stated
2,198
$167.84K
2.2%
2 Sep 2022
Chief Financial Officer
Sold, plan not stated
885
$69.95K
1.2%
8 Mar 2022
Chief Financial Officer
Sold, plan not stated
759
$53.21K
1.2%
4 Mar 2022
Chief Financial Officer
Sold, plan not stated
556
$39.15K
0.9%
3 Mar 2022
Chief Financial Officer
Sold, plan not stated
1,149
$85.60K
1.8%
2 Nov 2021
Chief Financial Officer
Sold, plan not stated
209
$22.42K
0.5%
2 Sep 2021
Chief Financial Officer
Sold, plan not stated
828
$114.46K
1.9%
12 Aug 2021
Chief Financial Officer
Sold, plan not stated
26,624
$3.75M
36.7%
8 Mar 2021
Chief Financial Officer
Sold, plan not stated
765
$100.07K
2.1%
4 Mar 2021
Chief Financial Officer
Sold, plan not stated
567
$77.99K
1.5%
2 Mar 2021
Chief Financial Officer
Sold, plan not stated
428
$65.08K
1.5%
2 Nov 2020
Chief Financial Officer
Sold, plan not stated
230
$27.00K
0.9%
21 decisions on file.